All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the European Hematology Association (EHA) 2023 Hybrid Congress, preliminary results from arm 4 of the phase II MANIFEST trial were reported.1 The MANIFEST trial is an ongoing 4-arm global study investigating pelabresib, an oral inhibitor of bromodomain and extra-terminal for the treatment of patients diagnosed with myelofibrosis and essential thrombocythemia (ET).1
Arm 4 of the study is currently evaluating pelabresib as a monotherapy for patients with high-risk ET who are refractory or intolerant to hydroxyurea treatment.1 We summarize the key preliminary findings from this treatment arm in the article below. For more recent developments in myeloproliferative neoplasms presented at the EHA 2023 Hybrid Congress, check out our list of hot abstracts here.
Table 1. Baseline patient characteristics*
Characteristic, % (unless otherwise stated) |
All patients |
---|---|
Median age, years |
64 |
Sex |
|
Female |
60 |
Male |
40 |
Median Hgb, g/dL |
13 |
Median platelet count, × 109/L |
722 |
Median WBC count, × 109/L |
7.9 |
Median spleen volume, cc |
402 |
Median TSS |
32.7 |
Median prior hydroxyurea duration, months |
103 |
Patients with ≥2 prior lines of therapy |
60 |
Prior thrombosis |
15 |
High-risk MF |
20 |
Driver mutations |
|
JAK2 |
45 |
CALR |
40 |
ASXL1 |
15 |
MPL |
5 |
Hgb, hemoglobin; MF, myelofibrosis; TSS, total symptom score; WBC, white blood cell. |
Preliminary results from this study highlight hematologic responses and symptom improvements among patients with high-risk ET. Treatment was tolerable and showed potential changes in biomarkers posttreatment. These results continue to support the evidence of a potential rationale for the use of pelabresib therapy for patients with ET.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox